BRONCHIAL THERMOPLASTY ONE "TOP 10 INNOVATIONS" OF
2007.
Asthmatx, Inc., Mountain View, Calif., a medical device company
that has developed a catheter-based procedure for the treatment for
asthma, has announced that bronchial thermoplasty, an . . .
OXIGENE GETS POSITIVE RESULTS OF PHASE II STUDY OF CA4P.
OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), Waltham, Mass., has
completed a Phase II Study in patients with advanced imageable
malignancies. This was a randomized open-label study of intravenous . . .
MEDICINOVA INITIATES PHASE II TRIAL FOR MN-221.
MediciNova, Inc., San Diego, Calif., a biopharmaceutical company
that is publicly traded on NASDAQ (Nasdaq:MNOV) and the Hercules Market
of the Osaka Securities Exchange (Code Number: 4875), has . . .
INNOVIVE ENROLLS FOR PHASE I OF INNO-305 PEPTIDE
IMMUNOTHERAPY.
INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH), a biopharmaceutical
company headquartered in Manhattan, announced today that a Phase I
clinical trial investigating INNO-305 in acute myelogenous . . .
IDM PHARMA SUBMITS NDA FOR JUNOVAN OSTEOSARCOMA
TREATMENT.
IDM Pharma (NASDAQ:IDMI), Irvine, Calif., has submitted an
electronic New Drug Application (NDA) to the U.S. Food and Drug
Administration (FDA) for Junovan (mifamurtide for injection), . . .
INFLAMMATORY ENZYNE LP-PLA2 PREDICTS RECURRENT STROKE.
diaDexus, Inc., South San Francisco has announced the publication
of a study showing that lipoprotein-associated phospholipase A2 (Lp-
PLA2), a cardiovascular-specific inflammatory enzyme . . .
CELLDEX/LUDWIG INST. FORM RESEARCH COLLABORATION.
Celldex Therapeutics, Inc. and the international Ludwig Institute
for Cancer Research (LICR) have announced a multi-year clinical research
collaboration focusing on a series of tumor-associated . . .
COLAZAL "FOOD EFFECT" APPLICATIOM GRANTED FDA
APPROVAL.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), Raleigh, N.C., has
announced that the U.S. Food and Drug Administration approved a
supplemental new drug application which provides for changes to . . .
VIOQUEST DOSES FIRST PATIENT IN PHASE I/IIA VQD-001
TRIAL.
Pharmaceuticals, Inc. (VQPH:OTC.BB), Basking Ridge, NJ, has dosed
the first patient in its Phase I/IIa clinical trial of VQD-001, Sodium
Stibogluconate (SSG), for evaluation of solid tumors, at the . . .
CALGENEX UNVEILS OMEGANOL FOR CHOLESTEROL/TRIGLYCERIDES.
Calgenex Corporation Tampa, Fla., has unveiled Omeganol(TM), the
first natural product for both cholesterol and triglyceride management,
combining high-concentration omega-3 fish oils and . . .
ALEXION ENROLLS ECULIZUMAB PHASE III SHEPHERD TRIAL.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), Cheshire, Conn., has
completed enrollment of the Phase III SHEPHERD trial of eculizumab in
patients with the chronic orphan blood disorder Paroxysmal . . .
GENVAC VACCINE ENTERS HIV HUMAN THERAPEUTIC CLINICAL
TRIALS.
GenVec, Inc. (Nasdaq:GNVC), Gaithersburg, Md., has announced today
that the first human therapeutic clinical trial involving the
company's adenoviral-vector technology used in an HIV . . .
KOSAN NAMES ITS LEAD HSP90 INHIBITOR COMPOUNDS.
Kosan Biosciences Incorporated (NASDAQ:KOSN), Hayward, Calif. has
selected nonproprietary compound names for its two lead Hsp90 inhibitor
compounds. KOS-953 is named tanespimycin and KOS-1022 is . . .
WYETH/PROGENICS START PHASE 2 TRIAL OF ORAL
METHYLNALREXONE.
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) have initiated a phase 2
clinical trial to evaluate once-daily dosing of oral . . .
CYTOGEN LAUNCHES SOLTAMOX ORAL LIQUID FOR BREAST CANCER.
Cytogen Corporation, Prineton, N.J. has announced that SOLTAMOX(tm)
(tamoxifen citrate, oral solution 10mg/5mL), the first liquid form of
the hormonal breast cancer therapy tamoxifen, is currently . . .
BIRCH BARK COMPOUND MAY BE POTENT PROSTATE CANCER
FIGHTER.
A compound found in the bark of the white birch tree -- betulonic
acid, a derivative of betulinol -- may finally have been rendered a
water-soluble, bio-available drug, and is already showing the . . .
ACCENTIA TO LICENSE ALL MAYO ANTIFUNGALS FOR CHRONIC
SINUSITIS.
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), Tampa, Fla., has
signed an amendment to its exclusive option agreement with the Mayo
Foundation for Medical Research and Education (Mayo Clinic) to . . .
AVI BIOPHARMA MODIFIES HEPATITIS C VIRUS CLINICAL STUDY.
AVI BioPharma, Inc. (Nasdaq:AVII), Portland, Ore., announced today
that it has entered patients to fill two new cohorts to extend the
duration of treatment with AVI-4065 in its hepatitis C virus . . .
ACAPODENE LOWERED CHOLESTEROL AND RAISED HDL IN PHASE
III.
GTx, Inc. (NASDAQ: GTXI}, Memphis, Tenn., the Men's Health
Biotech Company, has announced the results of a lipid interim analysis
of the pivotal Phase III ADT clinical trial evaluating oral, once . . .
NASTECH'S NASAL SPRAY ALTERNATIVE TO APPROVED INJECTED
PRODUCT.
In a preliminary Phase I clinical trial, a nasal spray dosage form
of Parathyroid Hormone (PTH1-34) developed by Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), Bothell, Wash., provided . . .
|
|